drugset
drugset / Trial / NCT04413214

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

NCT04413214 ↗

Phase 1 Completed 9 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

The trial is a study conducted to evaluate the safety, tolerability and PK characteristics of Carrimycin tablet and measure its anti-tumor efficacy initially in the treatment of patients with locally advanced, recurrent, or metastatic head and neck squamous cell carcinoma (non NPC).

Timeline

Start
2019-12-20
Primary completion
2022-12-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Carrimycin Unknown 200 mg Oral
Subject Carrimycin Unknown 400 mg Oral
Subject Carrimycin Unknown 600 mg Oral

Indications

oral cavity squamous cell carcinoma